Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Osteoporosis, Postmenopausal, Date of authorisation: 04/01/2007, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female, Date of authorisation: 02/02/2001, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Graft Rejection, Date of authorisation: 14/02/1996, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Lixiana, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/06/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Roteas, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/04/2017, Revision: 11, Status: Authorised

Explanatory note on pharmacovigilance fees payable to EMA (as of 4 October 2023)

Human medicines European public assessment report (EPAR): Rekovelle, follitropin delta, Anovulation, Date of authorisation: 12/12/2016, Revision: 6, Status: Authorised

Dacarbazine : List of nationally authorised medicinal products - PSUSA/00000919/202302

Human medicines European public assessment report (EPAR): Adynovi, rurioctocog alfa pegol, Hemophilia A, Date of authorisation: 08/01/2018, Revision: 10, Status: Authorised

Guidance on handling scientific committee/other (scientific) expert group member’s declared intention to become an employee in a pharmaceutical company, a medical device company or in the biotechnology sector